Source: FDA, National Drug Code (US) Revision Year: 2025
JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
The recommended dosage of JASCAYD is 18 mg twice daily, administered orally approximately 12 hours apart, with or without food.
Swallow JASCAYD tablets whole or dispersed in water [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
If a dose of JASCAYD is missed, advise the patient to take the next dose at the next scheduled time. Advise the patient to not make up for a missed dose.
The maximum recommended dosage of JASCAYD is 18 mg twice daily.
Reduce JASCAYD dosage to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors [see Drug Interactions (7.1)].
No dosage modification is recommended for JASCAYD when used concomitantly with moderate or weak CYP3A inhibitors.
Disperse JASCAYD tablet in water and administer as follows:
In the event of an overdosage with JASCAYD, monitor the patient for any signs or symptoms of adverse reactions and provide appropriate symptomatic treatment. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original container to protect from light.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.